Ronald Bailey
Neurology · Riverside, CANPI 1104808914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 434 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,419 and has fallen 98.5% since, to $37 in 2023.
Across 434 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Mallinckrodt Hospital Products Inc.$939
- AbbVie$921
- Genentech USA, Inc.$567
- Mallinckrodt Enterprises LLC$546
- Teva Pharmaceuticals USA, Inc.$527
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,333100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,015 |
| Mallinckrodt Hospital Products Inc. | 53 | $939 |
| AbbVie(2 entities) | 85 | $921 |
| Genentech USA, Inc. | 35 | $567 |
| Mallinckrodt Enterprises LLC | 28 | $546 |
| Teva Pharmaceuticals USA, Inc. | 54 | $527 |
| Amgen(2 entities) | 15 | $321 |
| Neurocrine Biosciences, Inc. | 14 | $265 |
| Sanofi | 9 | $165 |
| Biohaven Pharmaceuticals, Inc. | 7 | $147 |
| Tanabe Pharma America, Inc. | 6 | $134 |
| Livanova USA, Inc. | 9 | $115 |
| Lilly USA, LLC | 6 | $111 |
| Johnson & Johnson | 3 | $71 |
| Medtronic | 3 | $69 |
| Boston Scientific | 3 | $52 |
| Scilex Pharmaceuticals Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Novartis | 2 | $43 |
| EMD Serono, Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Lundbeck LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Merz North America, Inc. | 1 | $18 |
| MDD US Operations, LLC | 1 | $14 |
How this compares
$6,333 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.
Other neurology in Riverside
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.